文献速递肝病

肝脏脂肪定量在2型糖尿病患者心血管疾病风险评估中的临床效用

Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes.
PubMed 文献 · Aliment Pharmacol Ther · 2023-07-11

本研究为前瞻性队列的横断面分析,纳入391例年龄≥50岁的2型糖尿病成人,用磁共振成像质子密度脂肪分数(MRI-PDFF)定量肝脏脂肪,以MRI-PDFF≥14.6%为较高肝脏脂肪组。在校正年龄、性别、种族和BMI后,较高肝脏脂肪组心血管疾病风险(OR=4.04,95%CI:2.07-7.88,p<0.0001)和ASCVD风险评分(OR=2.85,95%CI:1.19-6.83,p=0.018)均更高。

要点

  • 在2型糖尿病成人中,MRI-PDFF≥14.6%组心血管疾病风险较<14.6%组升高(OR=4.04)。
  • 较高肝脏脂肪组ASCVD风险评分也更高(OR=2.85)。
  • 肝脏脂肪含量与心血管疾病风险的关联独立于年龄、性别、种族和BMI。

核心结论

  • 较高肝脏脂肪含量独立于年龄、性别、种族和BMI增加心血管疾病风险。
  • 这些发现提出是否应将肝脏脂肪定量纳入风险计算器以进一步分层心血管疾病高风险人群的问题。

研究设计与样本

  • 本研究为前瞻性队列的横断面分析,纳入391例年龄≥50岁的2型糖尿病成人(66%为女性),平均年龄64(±8)岁,平均BMI 30.8(±5.2)kg/m2。
  • 肝脏脂肪用磁共振成像质子密度脂肪分数(MRI-PDFF)定量,患者按MRI-PDFF≥14.6%和<14.6%分为较高肝脏脂肪组和较低肝脏脂肪组。
  • 共同主要结局为Framingham和动脉粥样硬化性心血管疾病(ASCVD)风险评分确定的心血管疾病风险,高风险定义为风险评分≥20%。

主要发现

  • 在校正年龄、性别、种族和BMI的多变量分析中,较高肝脏脂肪组心血管疾病风险高于较低肝脏脂肪组(OR=4.04,95%CI:2.07-7.88,p<0.0001)。
  • 较高肝脏脂肪组ASCVD风险评分也高于较低肝脏脂肪组(OR=2.85,95%CI:1.19-6.83,p=0.018)。

关键数值与推荐

  • 较高肝脏脂肪组定义为MRI-PDFF≥14.6%,较低肝脏脂肪组定义为MRI-PDFF<14.6%。
  • 高心血管疾病风险定义为Framingham或ASCVD风险评分≥20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are independent risk factors for cardiovascular disease (CVD). AIMS: To examine the clinical utility of liver fat quantification for determining CVD risk among a well-phenotyped cohort of patients with T2DM. METHODS: This was a cross-sectional analysis of a prospective cohort of adults aged ≥50 with T2DM. Liver fat was quantified with magnetic resonance imaging proton-density-fat-fraction (MRI-PDFF), an advanced imaging-based biomarker. Patients were stratified into a higher liver fat group (MRI-PDFF ≥ 14.6%), and a lower liver fat group (MRI-PDFF < 14.6%). The co-primary outcomes were CVD risk determined by Framingham and Atherosclerotic Cardiovascular Disease (ASCVD) risk scores. High CVD risk was defined by risk scores ≥20%. RESULTS: Of the 391 adults (66% female) in this study, the mean (±SD) age was 64 (±8) years and BMI 30.8 (±5.2) kg/m2 , respectively. In multivariable analysis, adjusted for age, gender, race, and BMI, patients in the higher liver fat group had higher CVD risk [OR = 4.04 (95% CI: 2.07-7.88, p < 0.0001)] and ASCVD risk score [OR = 2.85 (95% CI: 1.19-6.83, p = 0.018)], respectively. CONCLUSION: Higher liver fat content increases CVD risk independently of age, gender, ethnicity and BMI. These findings raise the question whether liver fat quantification should be incorporated into risk calculators to further stratify those with higher CVD risk.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kuo SZ, Cepin S, Bergstrom J, et al. Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes. Aliment Pharmacol Ther. 2023. PMID: 37431679. doi:10.1111/apt.17637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。